<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01808612</url>
  </required_header>
  <id_info>
    <org_study_id>14595</org_study_id>
    <secondary_id>B1Y-JE-HCLV</secondary_id>
    <nct_id>NCT01808612</nct_id>
  </id_info>
  <brief_title>A Study of Fluoxetine in Major Depressive Disorder (MDD) Short-Term Dosing</brief_title>
  <official_title>A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Parallel-Design Study to Evaluate the Short-Term, Fixed Dose Efficacy and Safety of LY110140 Once Daily Dosing in Japanese Patients With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the short-term efficacy and safety of Fluoxetine in
      Japanese adult participants with Major Depressive Disorder (MDD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change From Baseline to 6-Week Endpoint on the 21-Item Hamilton Depression Rating Scale (HAMD21) Total Score</measure>
    <time_frame>Baseline, 6 weeks</time_frame>
    <description>HAMD21 is a 21-item assessment used to measure depression severity. Items were rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score ranging from 0 (not at all depressed) to 64 (severely depressed). Least squares (LS) means were calculated using mixed-model repeated measures (MMRM) adjusting for the random effect of participant and fixed categorical effects of treatment, pooled investigative site, visit, and treatment-by-visit interaction, as well as the continuous fixed covariate of baseline HAMD21 total score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to 6-Week Endpoint on the HAMD21 Subscale Scores</measure>
    <time_frame>Baseline, 6 weeks</time_frame>
    <description>HAMD17 total scores and subscale scores from the HAMD21 are presented. HAMD17 is a 17-item assessment of depression severity (total scores range from 0-52). The Maier subscale (Items 1, 2, 7-10) represents the core symptoms of depression (0-24). Anxiety/Somatization subscale (Items 10-13, 15, 17) evaluates severity of psychic and somatic manifestations of anxiety as well as agitation (0-18). Retardation/Somatization subscale (Items 1, 7, 8, 14) evaluates dysfunction in mood, work, and sexual activity, as well as overall motor retardation (0-14). Sleep subscale (Items 4-6) assesses insomnia (0-6). Individual item scores may range from 0-4 or 0-2. Higher scores indicate more severe symptoms. LS means were calculated using MMRM adjusting for the random effect of participant and fixed categorical effects of treatment, pooled investigative site, visit, and treatment-by-visit interaction, as well as the continuous fixed covariate of baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Response at 6-Week Endpoint</measure>
    <time_frame>up to 6 weeks</time_frame>
    <description>The percentage of participants achieving a response (defined as a ≥50% improvement from baseline on the HAMD21 total score) was calculated by dividing the number of participants achieving a response at last observation by the total number of participants at risk, multiplied by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Remission at 6-Week Endpoint</measure>
    <time_frame>up to 6 weeks</time_frame>
    <description>The percentage of participants achieving a remission (defined as a HAMD21 total score ≤7) was calculated by dividing the number of participants achieving a remission at last observation by the total number of participants at risk, multiplied by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to 6-Week Endpoint on the Clinical Global Impression of Severity (CGI-S) Scale</measure>
    <time_frame>Baseline, 6 weeks</time_frame>
    <description>CGI-S measures severity of illness at the time of assessment with scores ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). LS means were calculated using MMRM adjusting for the random effect of participant and fixed categorical effects of treatment, pooled investigative site, visit, and treatment-by-visit interaction, as well as the continuous fixed covariate of baseline CGI-S score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline to 6-Week Endpoint in Sheehan Disability Scale (SDS) Total Score and Subscale Scores</measure>
    <time_frame>Baseline, up to 6 weeks</time_frame>
    <description>SDS was completed by the participant and was used to assess the effect of the participant's symptoms on their work/school (Item 1), social life/leisure activities (Item 2), and family life/home responsibilities (Item 3). Each item was measured on a 0 (not at all) to 10 (extremely) point scale with higher values indicating greater disruption. Total score was the sum of the 3 items and ranged from 0 to 30 with higher values indicating greater disruption in the participant's work/social/family life. LS means were calculated using analysis of covariance (ANCOVA) adjusting for treatment, pooled investigative site, and baseline SDS score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Suicidal Behaviors and Ideations Collected by Columbia - Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>Baseline through 6 weeks</time_frame>
    <description>C-SSRS captures occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal behavior is defined as a &quot;yes&quot; answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation is defined as a &quot;yes&quot; answer to any one of 5 suicidal ideation questions: wish to be dead, and 4 different categories of active suicidal ideation.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">513</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>20 mg Fluoxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 milligrams (mg) fluoxetine (capsules) administered orally, once daily, for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>40 mg Fluoxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 mg fluoxetine (capsules) administered orally, once daily, for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (capsules) administered orally, once daily, for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine</intervention_name>
    <arm_group_label>20 mg Fluoxetine</arm_group_label>
    <arm_group_label>40 mg Fluoxetine</arm_group_label>
    <other_name>LY110140</other_name>
    <other_name>Fluoxetine Hydrochloride</other_name>
    <other_name>Prozac</other_name>
    <other_name>Sarafem</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatient Japanese participants diagnosed with MDD

          -  Diagnosis of moderate or greater severity of MDD

          -  Agree to abstain from sexual activity or to use a reliable method of birth control

          -  Judged to be reliable (agree to keep appointments for clinic visits and to undergo all
             tests and examinations required by the protocol)

        Exclusion Criteria:

          -  Have previously been exposed to fluoxetine (LY110140) for any indication in the past

          -  Significant suicidal risk

          -  Have a current or previous diagnosis of bipolar disorder, psychotic depression,
             schizophrenia or other psychotic disorder, anorexia, bulimia, obsessive compulsive
             disorder, or post-traumatic stress disorder

          -  Have a history of substance abuse or dependence within the past 6 months, excluding
             caffeine and nicotine

          -  Have initiated, stopped, or changed the type or intensity of psychotherapy within 6
             weeks

          -  Have a history of electroconvulsive therapy (ECT), transcranial magnetic stimulation
             (TMS), or vagus nerve stimulation (VNS) within 1 year

          -  Have had treatment with a Monoamine oxidase inhibitor (MAOI) within 14 days

          -  Need to use thioridazine or pimozide during the study

          -  Have previously enrolled, completed, or withdrawn from this study

          -  Have a positive urine drug screen for drugs with abuse potential

          -  Female participants who are either pregnant, nursing, or have recently given birth, or
             male participants who are planning for their partners to be or become pregnant

          -  Have a history of seizure disorder

          -  Have frequent or severe allergic reactions to multiple medications

          -  Have a serious or unstable medical illness or condition, or psychological condition

          -  Participants deemed ineligible by the investigator or sub-investigator for other
             reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Aichi</city>
        <zip>471-8513</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chiba</city>
        <zip>270-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fukuoka</city>
        <zip>800-0226</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fukushima</city>
        <zip>961-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hiroshima</city>
        <zip>737-0143</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hokkaido</city>
        <zip>065-0012</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hyogo</city>
        <zip>651-0097</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kanagawa</city>
        <zip>238-0042</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kyoto</city>
        <zip>616-8421</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nagano</city>
        <zip>390-0303</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Okayama</city>
        <zip>700-0907</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Osaka</city>
        <zip>586-0012</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saitama</city>
        <zip>339-0057</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shiga</city>
        <zip>525-0037</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tochigi</city>
        <zip>321-0953</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tokyo</city>
        <zip>170-0002</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2013</study_first_submitted>
  <study_first_submitted_qc>March 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2013</study_first_posted>
  <results_first_submitted>April 24, 2015</results_first_submitted>
  <results_first_submitted_qc>April 24, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 12, 2015</results_first_posted>
  <last_update_submitted>April 24, 2015</last_update_submitted>
  <last_update_submitted_qc>April 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluoxetine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This study consisted of 3 periods: a single-blind screening period (1 week of placebo), a double-blind short-term treatment period (1 week of placebo followed by randomization in a 2:1:3 fashion to 20 milligrams [mg] fluoxetine, 40 mg fluoxetine, or placebo, respectively, for 6 weeks), and a single-blind discontinuation period (2 weeks of placebo).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>20 mg Fluoxetine</title>
          <description>Treatment Period: 20 milligrams (mg) fluoxetine (capsules) administered orally, once daily, for 6 weeks
Discontinuation Period: placebo (capsules) administered orally, once daily, for 2 weeks</description>
        </group>
        <group group_id="P2">
          <title>40 mg Fluoxetine</title>
          <description>Treatment Period: 40 mg fluoxetine (capsules) administered orally, once daily, for 6 weeks
Discontinuation Period: placebo (capsules) administered orally, once daily, for 2 weeks</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Treatment Period: placebo (capsules) administered orally, once daily, for 6 weeks
Discontinuation Period: placebo (capsules) administered orally, once daily, for 2 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="169"/>
                <participants group_id="P2" count="84"/>
                <participants group_id="P3" count="260"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="168">Only these participants were included in the study analyses (ie, Full Analysis Set).</participants>
                <participants group_id="P2" count="83">Only these participants were included in the study analyses (ie, Full Analysis Set).</participants>
                <participants group_id="P3" count="259">Only these participants were included in the study analyses (ie, Full Analysis Set).</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="154">67 participants who completed the Treatment Period did not enter the Discontinuation Period.</participants>
                <participants group_id="P2" count="77">39 participants who completed the Treatment Period did not enter the Discontinuation Period.</participants>
                <participants group_id="P3" count="246">101 participants who completed the Treatment Period did not enter the Discontinuation Period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Discontinuation Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="145"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="37"/>
                <participants group_id="P3" count="145"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants who received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>20 mg Fluoxetine</title>
          <description>20 mg fluoxetine (capsules) administered orally, once daily, for 6 weeks</description>
        </group>
        <group group_id="B2">
          <title>40 mg Fluoxetine</title>
          <description>40 mg fluoxetine (capsules) administered orally, once daily, for 6 weeks</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo (capsules) administered orally, once daily, for 6 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="168"/>
            <count group_id="B2" value="83"/>
            <count group_id="B3" value="259"/>
            <count group_id="B4" value="510"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.05" spread="11.19"/>
                    <measurement group_id="B2" value="39.58" spread="10.56"/>
                    <measurement group_id="B3" value="38.54" spread="11.65"/>
                    <measurement group_id="B4" value="39.20" spread="11.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="129"/>
                    <measurement group_id="B4" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="130"/>
                    <measurement group_id="B4" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="259"/>
                    <measurement group_id="B4" value="510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="259"/>
                    <measurement group_id="B4" value="510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="259"/>
                    <measurement group_id="B4" value="510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline to 6-Week Endpoint on the 21-Item Hamilton Depression Rating Scale (HAMD21) Total Score</title>
        <description>HAMD21 is a 21-item assessment used to measure depression severity. Items were rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score ranging from 0 (not at all depressed) to 64 (severely depressed). Least squares (LS) means were calculated using mixed-model repeated measures (MMRM) adjusting for the random effect of participant and fixed categorical effects of treatment, pooled investigative site, visit, and treatment-by-visit interaction, as well as the continuous fixed covariate of baseline HAMD21 total score.</description>
        <time_frame>Baseline, 6 weeks</time_frame>
        <population>Randomized participants who received at least 1 dose of study drug with a baseline and at least 1 post-baseline HAMD21 total score during the Treatment Period.</population>
        <group_list>
          <group group_id="O1">
            <title>20 mg Fluoxetine</title>
            <description>20 mg fluoxetine (capsules) administered orally, once daily, for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>40 mg Fluoxetine</title>
            <description>40 mg fluoxetine (capsules) administered orally, once daily, for 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo (capsules) administered orally, once daily, for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to 6-Week Endpoint on the 21-Item Hamilton Depression Rating Scale (HAMD21) Total Score</title>
          <description>HAMD21 is a 21-item assessment used to measure depression severity. Items were rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score ranging from 0 (not at all depressed) to 64 (severely depressed). Least squares (LS) means were calculated using mixed-model repeated measures (MMRM) adjusting for the random effect of participant and fixed categorical effects of treatment, pooled investigative site, visit, and treatment-by-visit interaction, as well as the continuous fixed covariate of baseline HAMD21 total score.</description>
          <population>Randomized participants who received at least 1 dose of study drug with a baseline and at least 1 post-baseline HAMD21 total score during the Treatment Period.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.18" spread="0.57"/>
                    <measurement group_id="O2" value="-6.25" spread="0.77"/>
                    <measurement group_id="O3" value="-6.91" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Approximately 522 participants were to be enrolled. Randomization was to be 2:1:3 (20 mg fluoxetine:40 mg fluoxetine:placebo). Assuming 5% of participants would have missing post-baseline data, the study had 85% power to detect an effect size of 0.33 (20 mg fluoxetine compared to placebo on HAMD21 total score) based on simulations with a 0.05 two-sided significance level.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.264</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.55</ci_lower_limit>
            <ci_upper_limit>2.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to 6-Week Endpoint on the HAMD21 Subscale Scores</title>
        <description>HAMD17 total scores and subscale scores from the HAMD21 are presented. HAMD17 is a 17-item assessment of depression severity (total scores range from 0-52). The Maier subscale (Items 1, 2, 7-10) represents the core symptoms of depression (0-24). Anxiety/Somatization subscale (Items 10-13, 15, 17) evaluates severity of psychic and somatic manifestations of anxiety as well as agitation (0-18). Retardation/Somatization subscale (Items 1, 7, 8, 14) evaluates dysfunction in mood, work, and sexual activity, as well as overall motor retardation (0-14). Sleep subscale (Items 4-6) assesses insomnia (0-6). Individual item scores may range from 0-4 or 0-2. Higher scores indicate more severe symptoms. LS means were calculated using MMRM adjusting for the random effect of participant and fixed categorical effects of treatment, pooled investigative site, visit, and treatment-by-visit interaction, as well as the continuous fixed covariate of baseline score.</description>
        <time_frame>Baseline, 6 weeks</time_frame>
        <population>Randomized participants who received at least 1 dose of study drug with a baseline and at least 1 post-baseline HAMD21 subscale score during the Treatment Period.</population>
        <group_list>
          <group group_id="O1">
            <title>20 mg Fluoxetine</title>
            <description>20 mg fluoxetine (capsules) administered orally, once daily, for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>40 mg Fluoxetine</title>
            <description>40 mg fluoxetine (capsules) administered orally, once daily, for 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo (capsules) administered orally, once daily, for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to 6-Week Endpoint on the HAMD21 Subscale Scores</title>
          <description>HAMD17 total scores and subscale scores from the HAMD21 are presented. HAMD17 is a 17-item assessment of depression severity (total scores range from 0-52). The Maier subscale (Items 1, 2, 7-10) represents the core symptoms of depression (0-24). Anxiety/Somatization subscale (Items 10-13, 15, 17) evaluates severity of psychic and somatic manifestations of anxiety as well as agitation (0-18). Retardation/Somatization subscale (Items 1, 7, 8, 14) evaluates dysfunction in mood, work, and sexual activity, as well as overall motor retardation (0-14). Sleep subscale (Items 4-6) assesses insomnia (0-6). Individual item scores may range from 0-4 or 0-2. Higher scores indicate more severe symptoms. LS means were calculated using MMRM adjusting for the random effect of participant and fixed categorical effects of treatment, pooled investigative site, visit, and treatment-by-visit interaction, as well as the continuous fixed covariate of baseline score.</description>
          <population>Randomized participants who received at least 1 dose of study drug with a baseline and at least 1 post-baseline HAMD21 subscale score during the Treatment Period.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAMD17 total score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.59" spread="0.53"/>
                    <measurement group_id="O2" value="-5.61" spread="0.71"/>
                    <measurement group_id="O3" value="-6.27" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maier subscale score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.35" spread="0.30"/>
                    <measurement group_id="O2" value="-3.39" spread="0.40"/>
                    <measurement group_id="O3" value="-3.30" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety/Somatization subscale score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.04" spread="0.21"/>
                    <measurement group_id="O2" value="-1.84" spread="0.28"/>
                    <measurement group_id="O3" value="-2.06" spread="0.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Retardation/Somatization subscale score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.00" spread="0.20"/>
                    <measurement group_id="O2" value="-2.21" spread="0.27"/>
                    <measurement group_id="O3" value="-2.23" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep subscale score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.83" spread="0.15"/>
                    <measurement group_id="O2" value="-0.81" spread="0.20"/>
                    <measurement group_id="O3" value="-1.10" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a Response at 6-Week Endpoint</title>
        <description>The percentage of participants achieving a response (defined as a ≥50% improvement from baseline on the HAMD21 total score) was calculated by dividing the number of participants achieving a response at last observation by the total number of participants at risk, multiplied by 100.</description>
        <time_frame>up to 6 weeks</time_frame>
        <population>Randomized participants who received at least 1 dose of study drug with a baseline and at least 1 post-baseline HAMD21 total score during the Treatment Period. Missing endpoints were imputed with the last observation carried forward (LOCF) method, using only post-baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>20 mg Fluoxetine</title>
            <description>20 mg fluoxetine (capsules) administered orally, once daily, for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>40 mg Fluoxetine</title>
            <description>40 mg fluoxetine (capsules) administered orally, once daily, for 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo (capsules) administered orally, once daily, for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Response at 6-Week Endpoint</title>
          <description>The percentage of participants achieving a response (defined as a ≥50% improvement from baseline on the HAMD21 total score) was calculated by dividing the number of participants achieving a response at last observation by the total number of participants at risk, multiplied by 100.</description>
          <population>Randomized participants who received at least 1 dose of study drug with a baseline and at least 1 post-baseline HAMD21 total score during the Treatment Period. Missing endpoints were imputed with the last observation carried forward (LOCF) method, using only post-baseline data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8"/>
                    <measurement group_id="O2" value="18.1"/>
                    <measurement group_id="O3" value="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a Remission at 6-Week Endpoint</title>
        <description>The percentage of participants achieving a remission (defined as a HAMD21 total score ≤7) was calculated by dividing the number of participants achieving a remission at last observation by the total number of participants at risk, multiplied by 100.</description>
        <time_frame>up to 6 weeks</time_frame>
        <population>Randomized participants who received at least 1 dose of study drug with a baseline (which had not achieved remission threshold criteria) and had at least 1 post-baseline HAMD21 total score during the Treatment Period. Missing endpoints were imputed with the last observation carried forward (LOCF) method, using only post-baseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>20 mg Fluoxetine</title>
            <description>20 mg fluoxetine (capsules) administered orally, once daily, for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>40 mg Fluoxetine</title>
            <description>40 mg fluoxetine (capsules) administered orally, once daily, for 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo (capsules) administered orally, once daily, for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Remission at 6-Week Endpoint</title>
          <description>The percentage of participants achieving a remission (defined as a HAMD21 total score ≤7) was calculated by dividing the number of participants achieving a remission at last observation by the total number of participants at risk, multiplied by 100.</description>
          <population>Randomized participants who received at least 1 dose of study drug with a baseline (which had not achieved remission threshold criteria) and had at least 1 post-baseline HAMD21 total score during the Treatment Period. Missing endpoints were imputed with the last observation carried forward (LOCF) method, using only post-baseline data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5"/>
                    <measurement group_id="O2" value="9.6"/>
                    <measurement group_id="O3" value="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to 6-Week Endpoint on the Clinical Global Impression of Severity (CGI-S) Scale</title>
        <description>CGI-S measures severity of illness at the time of assessment with scores ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). LS means were calculated using MMRM adjusting for the random effect of participant and fixed categorical effects of treatment, pooled investigative site, visit, and treatment-by-visit interaction, as well as the continuous fixed covariate of baseline CGI-S score.</description>
        <time_frame>Baseline, 6 weeks</time_frame>
        <population>Randomized participants who received at least 1 dose of study drug with a baseline and at least 1 post-baseline CGI-S score during the Treatment Period.</population>
        <group_list>
          <group group_id="O1">
            <title>20 mg Fluoxetine</title>
            <description>20 mg fluoxetine (capsules) administered orally, once daily, for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>40 mg Fluoxetine</title>
            <description>40 mg fluoxetine (capsules) administered orally, once daily, for 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo (capsules) administered orally, once daily, for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to 6-Week Endpoint on the Clinical Global Impression of Severity (CGI-S) Scale</title>
          <description>CGI-S measures severity of illness at the time of assessment with scores ranging from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). LS means were calculated using MMRM adjusting for the random effect of participant and fixed categorical effects of treatment, pooled investigative site, visit, and treatment-by-visit interaction, as well as the continuous fixed covariate of baseline CGI-S score.</description>
          <population>Randomized participants who received at least 1 dose of study drug with a baseline and at least 1 post-baseline CGI-S score during the Treatment Period.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" spread="0.08"/>
                    <measurement group_id="O2" value="-0.67" spread="0.11"/>
                    <measurement group_id="O3" value="-0.81" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline to 6-Week Endpoint in Sheehan Disability Scale (SDS) Total Score and Subscale Scores</title>
        <description>SDS was completed by the participant and was used to assess the effect of the participant's symptoms on their work/school (Item 1), social life/leisure activities (Item 2), and family life/home responsibilities (Item 3). Each item was measured on a 0 (not at all) to 10 (extremely) point scale with higher values indicating greater disruption. Total score was the sum of the 3 items and ranged from 0 to 30 with higher values indicating greater disruption in the participant's work/social/family life. LS means were calculated using analysis of covariance (ANCOVA) adjusting for treatment, pooled investigative site, and baseline SDS score.</description>
        <time_frame>Baseline, up to 6 weeks</time_frame>
        <population>Randomized participants who received at least 1 dose of study drug with a baseline and at least 1 post-baseline SDS score during the Treatment Period. Missing endpoints were imputed with the last observation carried forward (LOCF) method, using only postbaseline data.</population>
        <group_list>
          <group group_id="O1">
            <title>20 mg Fluoxetine</title>
            <description>20 mg fluoxetine (capsules) administered orally, once daily, for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>40 mg Fluoxetine</title>
            <description>40 mg fluoxetine (capsules) administered orally, once daily, for 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo (capsules) administered orally, once daily, for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to 6-Week Endpoint in Sheehan Disability Scale (SDS) Total Score and Subscale Scores</title>
          <description>SDS was completed by the participant and was used to assess the effect of the participant's symptoms on their work/school (Item 1), social life/leisure activities (Item 2), and family life/home responsibilities (Item 3). Each item was measured on a 0 (not at all) to 10 (extremely) point scale with higher values indicating greater disruption. Total score was the sum of the 3 items and ranged from 0 to 30 with higher values indicating greater disruption in the participant's work/social/family life. LS means were calculated using analysis of covariance (ANCOVA) adjusting for treatment, pooled investigative site, and baseline SDS score.</description>
          <population>Randomized participants who received at least 1 dose of study drug with a baseline and at least 1 post-baseline SDS score during the Treatment Period. Missing endpoints were imputed with the last observation carried forward (LOCF) method, using only postbaseline data.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="167"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total score (n=167, 81, 259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.76" spread="0.59"/>
                    <measurement group_id="O2" value="-1.55" spread="0.78"/>
                    <measurement group_id="O3" value="-1.99" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Work/School subscale score (n=143, 64, 226)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.79" spread="0.27"/>
                    <measurement group_id="O2" value="-0.34" spread="0.36"/>
                    <measurement group_id="O3" value="-0.88" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social/Leisure subscale score (n=167, 81, 259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.66" spread="0.23"/>
                    <measurement group_id="O2" value="-0.81" spread="0.30"/>
                    <measurement group_id="O3" value="-0.70" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Family/Home subscale score (n=167, 81, 259)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="0.21"/>
                    <measurement group_id="O2" value="-0.30" spread="0.28"/>
                    <measurement group_id="O3" value="-0.41" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Suicidal Behaviors and Ideations Collected by Columbia - Suicide Severity Rating Scale (C-SSRS)</title>
        <description>C-SSRS captures occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal behavior is defined as a &quot;yes&quot; answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation is defined as a &quot;yes&quot; answer to any one of 5 suicidal ideation questions: wish to be dead, and 4 different categories of active suicidal ideation.</description>
        <time_frame>Baseline through 6 weeks</time_frame>
        <population>Randomized participants who received at least 1 dose of study drug with at least 1 post-baseline C-SSRS score during the Treatment Period.</population>
        <group_list>
          <group group_id="O1">
            <title>20 mg Fluoxetine</title>
            <description>20 mg fluoxetine (capsules) administered orally, once daily, for 6 weeks</description>
          </group>
          <group group_id="O2">
            <title>40 mg Fluoxetine</title>
            <description>40 mg fluoxetine (capsules) administered orally, once daily, for 6 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo (capsules) administered orally, once daily, for 6 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Suicidal Behaviors and Ideations Collected by Columbia - Suicide Severity Rating Scale (C-SSRS)</title>
          <description>C-SSRS captures occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal behavior is defined as a &quot;yes&quot; answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation is defined as a &quot;yes&quot; answer to any one of 5 suicidal ideation questions: wish to be dead, and 4 different categories of active suicidal ideation.</description>
          <population>Randomized participants who received at least 1 dose of study drug with at least 1 post-baseline C-SSRS score during the Treatment Period.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="259"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Suicidal behavior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Suicidal ideation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Serious adverse events (SAEs) and non-serious AEs were reported for all randomized participants who received at least 1 dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo (Treatment Period)</title>
          <description>Adverse events (AEs) which occurred during the Treatment Period for participants who received placebo administered orally, once daily, for 6 weeks during the Treatment Period</description>
        </group>
        <group group_id="E2">
          <title>20 mg Fluoxetine (Treatment Period)</title>
          <description>AEs which occurred during the Treatment Period for participants who received 20 mg fluoxetine administered orally, once daily, for 6 weeks during the Treatment Period</description>
        </group>
        <group group_id="E3">
          <title>40 mg Fluoxetine (Treatment Period)</title>
          <description>AEs which occurred during the Treatment Period for participants who received 40 mg fluoxetine administered orally, once daily, for 6 weeks during the Treatment Period</description>
        </group>
        <group group_id="E4">
          <title>Placebo (Discontinuation From Placebo)</title>
          <description>AEs which occurred during the Discontinuation Period for participants who received placebo during the Treatment Period and who received placebo administered orally, once daily, for 2 weeks during the Discontinuation Period</description>
        </group>
        <group group_id="E5">
          <title>Placebo (Discontinuation From 20 mg Fluoxetine)</title>
          <description>AEs which occurred during the Discontinuation Period for participants who received 20 mg fluoxetine during the Treatment Period and who received placebo administered orally, once daily, for 2 weeks during the Discontinuation Period</description>
        </group>
        <group group_id="E6">
          <title>Placebo (Discontinuation From 40 mg Fluoxetine)</title>
          <description>AEs which occurred during the Discontinuation Period for participants who received 40 mg fluoxetine during the Treatment Period and who received placebo administered orally, once daily, for 2 weeks during the Discontinuation Period</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Infertility male</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="130"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="259"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="168"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="83"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="145"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Thyroiditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="259"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="259"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="168"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="259"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="168"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Gastritis atrophic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Gingival inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="168"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholic liver disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Enterocolitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="259"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="168"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Heat illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="259"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="259"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Electrocardiogram qt prolonged</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Electrocardiogram st segment depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Endoscopy large bowel</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Protein urine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Qrs axis abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Urine ketone body present</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="168"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hypercreatininaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Duodenal neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Anterograde amnesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="259"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="259"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="168"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Impatience</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="168"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Ejaculation delayed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="130"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dyshidrotic eczema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="168"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Miliaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="259"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="168"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="259"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="168"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="145"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

